You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

17 Results
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Jun 2021
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Palliative
Jun 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Aug 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative, Curative, Adjuvant
Feb 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
May 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Curative
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Aug 2021
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Curative, Palliative
Feb 2021
Drug
Other Name(s): Imfinzi®
May 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Liposomal DOXOrubicin - Single Agent Treatment of Platinum Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer
New Drug Funding Program
    Liposomal Doxorubicin - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer
Mar 2025

Pages